Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case …
antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case …
[HTML][HTML] Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Abstract Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen
(BCMA) mediate profound responses in patients with multiple myeloma, but most patients do …
(BCMA) mediate profound responses in patients with multiple myeloma, but most patients do …
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells
In 2 complementary Letters to Blood, Karschnia et al and Graham et al provide new insights
into the neurological toxicities that are observed with B-cell maturation antigen–directed …
into the neurological toxicities that are observed with B-cell maturation antigen–directed …
[HTML][HTML] B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I …
AD Cohen, AL Garfall, EA Stadtmauer, SF Lacey… - Blood, 2016 - Elsevier
Background: BCMA is expressed on MM cells, and CAR T cells targeting BCMA have pre-
clinical anti-MM activity. CART-BCMA is an autologous T cell product engineered by …
clinical anti-MM activity. CART-BCMA is an autologous T cell product engineered by …
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
MC Da Vià, O Dietrich, M Truger, P Arampatzi, J Duell… - Nature medicine, 2021 - nature.com
B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …
[HTML][HTML] Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell leukemia
X Li, X Guo, Y Zhu, G Wei, Y Zhang, X Li, H Xu, J Cui… - Molecular Therapy, 2021 - cell.com
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
hematological malignancies due to the prominent anti-tumor effects. B cell maturation …
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
8505 Background: JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T (CAR-T) cell
therapy containing 2 BCMA-targeting single-domain antibodies. Here we present updated …
therapy containing 2 BCMA-targeting single-domain antibodies. Here we present updated …
[HTML][HTML] Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy
JG Berdeja, M Alsina, ND Shah, DS Siegel… - Blood, 2019 - Elsevier
Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B cell
maturation antigen (BCMA) has shown promising results for the treatment of relapsed …
maturation antigen (BCMA) has shown promising results for the treatment of relapsed …
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
[HTML][HTML] Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy
N Shah, M Alsina, DS Siegel, S Jagannath, D Madduri… - Blood, 2018 - Elsevier
Introduction: Immunomodulatory chimeric antigen receptor (CAR) T cell therapy directed
against B-cell maturation antigen (BCMA) has shown promising results for the treatment of …
against B-cell maturation antigen (BCMA) has shown promising results for the treatment of …